How to cite item

Treating acquired resistance to EGFR-tyrosine kinase inhibitors: Still a work in progress

   
@article{TLCR408,
	author = {Nathan A. Pennell},
	title = {Treating acquired resistance to EGFR-tyrosine kinase inhibitors: Still a work in progress},
	journal = {Translational Lung Cancer Research},
	volume = {1},
	number = {2},
	year = {2012},
	keywords = {},
	abstract = {While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizingmutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFRtyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance tothese agents. One of the strategies being tested to overcome acquired resistance to EGFR TKIs is the use ofirreversible EGFR inhibitors such as afatinib. In the randomized phase 2b/3 LUX-Lung 1 trial in advancedNSCLC patients who progressed after at least 12 weeks of benefit from EGFR TKIs, afatinib failed toimprove overall survival compared to placebo. Although the liberal entry criteria likely allowed the inclusionof some patients without true acquired resistance, the failure of this study calls into question the viability ofirreversible EGFR inhibitors in this patient population.},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/408}
}